Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous isatuximab with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma
NCT05704049Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Apr 2023
- Primary completion
- Dec 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of isatuximab in multiple myeloma (MM), sponsored by Sanofi. Started Apr 2023; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05704049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05704049.